Drug stock Moderna (MRNA) is pulling back to a historically bullish trendline and has plenty of contrarian signals flashing ...
Moderna (MRNA) valuation in focus: weak Q2, cash outlook, FDA win for mFLUSIVA, pipeline risks and sales hurdles.
Phase 1 trial will evaluate safety and immune response for a strain of Ebola virus disease with no licensed vaccines ...
Operator: Good day, and thank you for standing by. Welcome to the Moderna Second Quarter 2026 Conference Call. Please be ...
Moderna’s mRNA-based flu vaccine, mFlusiva, is approved by the Food and Drug Administration for adults aged 50 and over.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results